You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Recombinant Therapeutic Antibodies And Proteins Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Market Analysis and Insights: Global Recombinant Therapeutic Antibodies and Proteins Market
The global Recombinant Therapeutic Antibodies and Proteins market size is projected to reach US$ 143680 million by 2026, from US$ 89490 million in 2019, at a CAGR of 6.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Therapeutic Antibodies and Proteins market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Therapeutic Antibodies and Proteins market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Therapeutic Antibodies and Proteins market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Therapeutic Antibodies and Proteins market.
Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Coagulation Factors
Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Application
Infectious Disease
Cardiovascular Disease
Based on regional and country-level analysis, the Recombinant Therapeutic Antibodies and Proteins market has been segmented as follows:
North America
United States
Rest of Europe
South Korea
Southeast Asia
Rest of Asia-Pacific
Latin America
Middle East & Africa
Saudi Arabia
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Recombinant Therapeutic Antibodies and Proteins market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
The following players are covered in this report:
Eli Lilly
Johnson and Johnson
Novo Nordisk
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Plasma Protein
1.2.3 Fusion Proteins
1.2.4 Monoclonal Antibodies
1.2.5 Hormones
1.2.6 Enzyme
1.2.7 Coagulation Factors
1.2.8 Others
1.3 Market by Application
1.3.1 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Hematology
1.3.4 Immunology
1.3.5 Endocrinology
1.3.6 Infectious Disease
1.3.7 Cardiovascular Disease
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2016-2027)
2.2 Recombinant Therapeutic Antibodies and Proteins Growth Trends by Regions
2.2.1 Recombinant Therapeutic Antibodies and Proteins Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Share by Regions (2016-2021)
2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2022-2027)
2.3 Recombinant Therapeutic Antibodies and Proteins Industry Dynamic
2.3.1 Recombinant Therapeutic Antibodies and Proteins Market Trends
2.3.2 Recombinant Therapeutic Antibodies and Proteins Market Drivers
2.3.3 Recombinant Therapeutic Antibodies and Proteins Market Challenges
2.3.4 Recombinant Therapeutic Antibodies and Proteins Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue
3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2016-2021)
3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2016-2021)
3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
3.4 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio
3.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2020
3.5 Recombinant Therapeutic Antibodies and Proteins Key Players Head office and Area Served
3.6 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
3.7 Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Type
4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2016-2021)
4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2022-2027)

5 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Application
5.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Application (2016-2021)
5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
6.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type
6.2.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
6.2.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
6.2.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application
6.3.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
6.3.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
6.3.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country
6.4.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
6.4.2 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
7.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type
7.2.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
7.2.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
7.2.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application
7.3.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
7.3.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
7.3.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country
7.4.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
7.4.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
8.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type
8.2.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
8.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application
8.3.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
8.4 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region
8.4.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
9.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type
9.2.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
9.2.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
9.2.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
9.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application
9.3.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
9.3.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
9.3.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
9.4 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country
9.4.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
9.4.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2016-2027)
10.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type
10.2.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2016-2027)
10.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application
10.3.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2016-2027)
10.4 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country
10.4.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Details
11.1.2 Abbott Business Overview
11.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction
11.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.1.5 Abbott Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction
11.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction
11.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.3.5 Biogen Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction
11.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction
11.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.5.5 Roche Recent Development
11.6 Johnson and Johnson
11.6.1 Johnson and Johnson Company Details
11.6.2 Johnson and Johnson Business Overview
11.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction
11.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.6.5 Johnson and Johnson Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction
11.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Novo Nordisk
11.8.1 Novo Nordisk Company Details
11.8.2 Novo Nordisk Business Overview
11.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction
11.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.8.5 Novo Nordisk Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction
11.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.9.5 Pfizer Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction
11.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2016-2021)
11.10.5 Sanofi Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 130